Business
Voyageur Introduces Five New Barium Contrast Formulations Setting New Standards in Medical Imaging Industry
(TheNewswire) Calgary, Alberta, Canada, September 5, 2024 – TheNewswire –...
About this update from Voyageur Pharmaceuticals Ltd
[{"type":"text","content":"Voyageur Introduces Five New Barium Contrast Formulations Setting New Standards in Medical Imaging Industry\n\n\n (TheNewswire)\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Calgary, Alberta, Canada, September 5, 2024 –\n \n\n TheNewswire –\n \n\n Voyageur Pharmaceuticals Ltd\n \n\n . (TSX.V: VM) (USA: VYYRF) (\"Voyageur\" or the\n\"Company\") announces that in an innovative endeavor,\n \n\n it has completed formulation work on its new\nproduct line of 5 Health Canada licensed products. Voyageur has\nengineered these advanced formulations to improve existing market\nstandards, prioritizing enhanced value for stakeholders. By\nintroducing distinct brands, Vision and Smooth barium contrast agents,\nVoyageur brings versatility and performance to medical diagnostics.\nNotably, these products will be classified as new drugs under the\n505(b)(2) FDA drug pathway, a streamlined process that enables drug\napproval based on existing data sources, expediting approval timelines\nand reducing costs compared to a full NDA submission.  Creating new\nproducts versus manufacturing generic products creates a new level of\ncompetitiveness for Voyageur.\n \n\n\n\n Voyageur has completed multiple test pilot batches for\nits full suite of products and is now proceeding with pilot batches\nfor patient testing.  Voyageur is progressing to the final phase of\nclinical testing, utilizing its products in patients for X-ray and\nComputed Tomography (CT). Upon the completion of these evaluations,\nfocusing on the quality of imaging results, Voyageur plans to launch\nits products in the Canadian and International markets. The patient\ntrials are anticipated to take approximately two months, encompassing\ncomprehensive analyses of imaging scans and the preparation of\nindependent white papers for each product. All testing is following\nguidelines for future FDA licensing.\n \n\n\n\n Brent Willis, CEO of Voyageur, explains,\n\"\n \n\n Voyageur highlights that transitioning\nfrom generic formulations to a more sophisticated product line\ndemanded a significant investment of time and resources. This\nstrategic shift is projected to deliver long-term advantages. After\nrigorously assessing each product's performance, Voyageur intends to\nseek FDA approval for these formulations in the U.S. market through\nthe 505(b)(2) ...